论文部分内容阅读
目的比较治疗组(奥扎格雷钠与尼莫地平联用)与对照组(单用奥扎格雷钠)的临床疗效。方法2006、2007两年我院神经内科选用60例脑梗死住院患者,随机分为两组。治疗组(奥扎格雷钠、尼莫地平联用)30例,对照组(单用奥扎格雷钠)30例,两组进行临床对比观察。结果治疗前两组神经功能缺损评分无显著性差异。治疗后第7、14、21天神经功能缺损评分治疗组明显高于对照组。结论尼莫地平能显著改善神经功能缺损症状,尤其适用于大面积脑梗死。
Objective To compare the clinical efficacy of sodium ozagrel and nimodipine in treatment group and control group (sodium ozagrel alone). Methods In 2006 and 2007, 60 cases of cerebral infarction inpatients were randomly divided into two groups. Thirty patients in the treatment group (sodium ozagrel, nimodipine) and 30 in the control group (sodium ozagrel alone), the two groups were compared clinically. Results Before treatment, there was no significant difference in neurological deficit scores between the two groups. On the 7th, 14th and 21st days after treatment, the neurological deficit score was significantly higher in the treatment group than in the control group. Conclusion Nimodipine can significantly improve the symptoms of neurological deficits, especially for large area cerebral infarction.